Funding for this research was provided by:
Japan Agency for Medical Research and Development (19lm0203054h0002, 19ek0109327h0002, JP18kk0305003h0003)
Japan Society for the Promotion of Science (15H05721)
Received: 15 May 2020
Accepted: 21 June 2021
First Online: 23 July 2021
: S.M. and S.S. are employees of Kyorin Pharmaceutical Co., Ltd. M.H. is a founder, shareholder, and member of the scientific advisory board of KinoPharma, Inc., and BTB Drug Development Research Center Co., Ltd. The remaining authors declare no competing interests.